Global Novel Coronavirus Inactivated Vaccine Market Growth 2025-2031

The global Novel Coronavirus Inactivated Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022.

In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs.

However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need.

Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

ReportPrime, Inc. (LPI) ' newest research report, the “Novel Coronavirus Inactivated Vaccine Industry Forecast” looks at past sales and reviews total world Novel Coronavirus Inactivated Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Novel Coronavirus Inactivated Vaccine sales for 2025 through 2031. With Novel Coronavirus Inactivated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Novel Coronavirus Inactivated Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Novel Coronavirus Inactivated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyzes the strategies of leading global companies with a focus on Novel Coronavirus Inactivated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Novel Coronavirus Inactivated Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Novel Coronavirus Inactivated Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.

With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Novel Coronavirus Inactivated Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Novel Coronavirus Inactivated Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Adult
• Child

Segmentation by Application:

• Hospital
• Clinic

Market by Region:

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage:

• Inovio Pharmaceuticals
• Moderna
• GlaxoSmithKline
• Pfizer
• Johnson&Johnson
• Heat Biologics
• Sanofi
• Beijing Institute of Biological Products Co., Ltd
• Beijing Kexing Zhongwei Biotechnology Co., Ltd
• Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd
• Wuhan Institute of Biological Products Co., Ltd

Key Questions Addressed in this Report: